First-Line Treatment of _ALK_-Positive NSCLC
Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (_ALK_) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed metastatic _ALK_-positive NSCLC treated wit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-11-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2019.02.009 |